Back to top
more

KalVista Pharmaceuticals, Inc. (KALV)

(Delayed Data from NSDQ)

$15.99 USD

15.99
346,034

-0.96 (-5.66%)

Updated Oct 21, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.44%
2Buy17.91%
3Hold9.42%
4Sell4.91%
5Strong Sell1.79%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (175 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States.

General Information

KalVista Pharmaceuticals Inc

55 Cambridge Parkway Suite 901E

CAMBRIDGE, MA 02142

Phone: 857-999-0075

Fax: 866-553-3269

Web: http://www.kalvista.com

Email: ir@kalvista.com

Industry Medical - Drugs
Sector Medical
Fiscal Year End April
Last Reported Quarter 7/31/2020
Next EPS Date 12/1/2020

EPS Information

Current Quarter EPS Consensus Estimate -0.70
Current Year EPS Consensus Estimate -2.78
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 12/1/2020

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 16.95
52 Week High 19.41
52 Week Low 5.61
Beta 2.32
20 Day Moving Average 52,745.95
Target Price Consensus 28.57

KALV

% Price Change
4 Week 25.83
12 Week 53.26
YTD -4.83
% Price Change Relative to S&P 500
4 Week 21.17
12 Week 43.25
YTD -18.53
Share Information
Shares Outstanding (millions) 17.91
Market Capitalization (millions) 303.53
Short Ratio NA
Last Split Date 11/22/2016
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -45.24%
vs. Previous Quarter -64.86%
   
Sales Growth
vs. Previous Year 30.69%
vs. Previous Quarter 142.49%
   
Price Ratios
Price/Book 4.08
Price/Cash Flow NA
Price / Sales 23.92
ROE
7/31/20 -37.71
4/30/20 -31.21
1/31/20 -32.17
ROA
7/31/20 -33.31
4/30/20 -27.25
1/31/20 -27.42
Current Ratio
7/31/20 9.49
4/30/20 11.49
1/31/20 10.14
Quick Ratio
7/31/20 9.49
4/30/20 11.49
1/31/20 10.14
Operating Margin
7/31/20 NA
4/30/20 -229.45
1/31/20 -263.38
Net Margin
7/31/20 NA
4/30/20 -229.45
1/31/20 -263.38
Pre-Tax Margin
7/31/20 -350.99
4/30/20 -230.42
1/31/20 -262.33
Book Value
7/31/20 4.16
4/30/20 4.69
1/31/20 5.03
Inventory Turnover
7/31/20 NA
4/30/20 NA
1/31/20 NA
Debt-to-Equity
7/31/20 0.00
4/30/20 0.00
1/31/20 0.00
Debt to Capital
7/31/20 0.00
4/30/20 0.00
1/31/20 0.00